Resources from the same session
Clinical and molecular characteristics of resistance to immunotherapy
Presenter: Thomas Gajewski
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Future combinations: Intralesional and other immunotherapy combinations
Presenter: Olivier Michielin
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Future strategies: Sequencing versus combinations in targeted and immune therapy
Presenter: Paolo Ascierto
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Olivier Michielin
Session: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
Resources:
Webcast